Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy

NCT01679197 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Fatty Liver Disease, Nonalcoholic
Nonalcoholic Steatohepatitis
Lipodystrophy

Interventions

DRUG: Metreleptin

Sponsor

University of Michigan

Collaborators

[object Object]